These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 33807818)

  • 1. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
    Rogliani P; Chetta A; Cazzola M; Calzetta L
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818
    [No Abstract]   [Full Text] [Related]  

  • 2. Covid-19 vaccines and variants of concern: A review.
    Hadj Hassine I
    Rev Med Virol; 2022 Jul; 32(4):e2313. PubMed ID: 34755408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants.
    Padhiar NH; Liu JB; Wang X; Wang XL; Bodnar BH; Khan S; Wang P; Khan AI; Luo JJ; Hu WH; Ho WZ
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.
    Upreti S; Samant M
    Pharm Res; 2022 Sep; 39(9):2119-2134. PubMed ID: 35773445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.
    Pascuale CA; Varese A; Ojeda DS; Pasinovich ME; Lopez L; Rossi AH; Rodriguez PE; Miglietta EA; ; Mazzitelli I; Di Diego Garcia F; Sanchez L; Rouco SO; Gonzalez Lopez Ledesma MM; Zurano JP; Mazzitelli B; Scruzzi G; Barbero P; Cardozo D; Gallego S; Borda M; Diaz M; ; ; Ridao F; Rosales AB; ; Bhon J; Talia JM; Diangelo ME; Lacaze MA; ; Aime B; Gutierrez SI; Ercole R; Toro R; Tau L; Delaplace L; Compagnucci MF; ; Sartori C; Desimone I; Echegoyen C; Velazquez P; Testa C; ; Hozbor D; Docena G; Laino CH; Kreplak N; Pifano M; Barbas G; Rearte A; Vizzotti C; Castelli JM; Geffner J; Gamarnik AV
    Cell Rep Med; 2022 Aug; 3(8):100706. PubMed ID: 35926505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
    Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J
    Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
    Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
    Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022.
    Malagón-Rojas J; Mercado-Reyes M; Toloza-Pérez YG; Galindo M; Palma RM; Catama J; Bedoya JF; Parra-Barrera EL; Meneses X; Barbosa J; Tavera-Rodríguez P; Bermúdez-Forero A; Ospina-Martínez ML
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.
    Doroftei B; Ciobica A; Ilie OD; Maftei R; Ilea C
    Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33804914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
    Noor R; Shareen S; Billah M
    Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.
    Muñoz-Valle JF; Sánchez-Zuno GA; Matuz-Flores MG; Hernández-Ramírez CO; Díaz-Pérez SA; Baños-Hernández CJ; Turrubiates-Hernández FJ; Vega-Magaña AN; Hernández-Bello J
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.
    Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY
    Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624
    [No Abstract]   [Full Text] [Related]  

  • 14. Humoral and cellular immune memory to four COVID-19 vaccines.
    Zhang Z; Mateus J; Coelho CH; Dan JM; Moderbacher CR; Gálvez RI; Cortes FH; Grifoni A; Tarke A; Chang J; Escarrega EA; Kim C; Goodwin B; Bloom NI; Frazier A; Weiskopf D; Sette A; Crotty S
    bioRxiv; 2022 Mar; ():. PubMed ID: 35350195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges.
    Rahman MM; Masum MHU; Wajed S; Talukder A
    Virusdisease; 2022 Mar; 33(1):1-22. PubMed ID: 35127995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration].
    Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1237-1243. PubMed ID: 36257986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.
    Hernández-Bello J; Morales-Núñez JJ; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Balcázar-Félix P; Gutiérrez-Brito JA; Lomelí-Nieto JA; Muñoz-Valle JF
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
    Lyke KE; Atmar RL; Dominguez Islas C; Posavad CM; Deming ME; Branche AR; Johnston C; El Sahly HM; Edupuganti S; Mulligan MJ; Jackson LA; Rupp RE; Rostad CA; Coler RN; Bäcker M; Kottkamp AC; Babu TM; Dobrzynski D; Martin JM; Brady RC; Frenck RW; Rajakumar K; Kotloff K; Rouphael N; Szydlo D; PaulChoudhury R; Archer JI; Crandon S; Ingersoll B; Eaton A; Brown ER; McElrath MJ; Neuzil KM; Stephens DS; Post DJ; Lin BC; Serebryannyy L; Beigel JH; Montefiori DC; Roberts PC;
    NPJ Vaccines; 2023 Jul; 8(1):98. PubMed ID: 37433788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of COVID-19 Vaccines and Their Evidence in Older Adults.
    Teo SP
    Ann Geriatr Med Res; 2021 Mar; 25(1):4-9. PubMed ID: 33550776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.
    van der Lubbe JEM; Rosendahl Huber SK; Vijayan A; Dekking L; van Huizen E; Vreugdenhil J; Choi Y; Baert MRM; Feddes-de Boer K; Izquierdo Gil A; van Heerden M; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; de Waal L; Stittelaar KJ; Tolboom JTBM; Serroyen J; Muchene L; van der Fits L; Rutten L; Langedijk JPM; Barouch DH; Schuitemaker H; Zahn RC; Wegmann F
    NPJ Vaccines; 2021 Mar; 6(1):39. PubMed ID: 33741993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.